Barrow, Hanley, Mewhinney & Strauss
LFCR icon

Barrow, Hanley, Mewhinney & Strauss’s Lifecore Biomedical LFCR Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,843
Closed -$74K – 433
2017
Q4 		$74K Sell
5,843
-12,731
-69% -$161K ﹤0.01% 343
2017
Q3 		$241K Buy
+18,574
New +$245K ﹤0.01% 331

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's LFCR Position: Q1 2018 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Lifecore Biomedical (LFCR) in Q1 2018, closing a stake of 5,843 shares — an estimated $74K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in LFCR in Q3 2017 and held it in 2 quarters. The position peaked at $241K in Q3 2017. 89 funds tracked by Wall St. Rank hold LFCR as of Q1 2018.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Lifecore Biomedical position as of Q1 2018 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 5,843 Lifecore Biomedical shares in Q1 2018, an estimated $74K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Lifecore Biomedical in Q3 2017 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Lifecore Biomedical position peaked at $241K in Q3 2017.
  • 89 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2018.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q1 2018, filed 14 May 2018.